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Background: Live viral vaccines are generally contraindicated in patients with combined
immunodeficiency including cartilage-hair hypoplasia (CHH); however, they may be
tolerated in milder syndromes. We evaluated the safety and efficacy of live viral vaccines
in patients with CHH.
Methods: We analyzed hospital and immunization records of 104 patients with CHH
and measured serum antibodies to measles, mumps, rubella, and varicella zoster virus
(VZV) in all patients who agreed to blood sampling (n = 50). We conducted a clinical
trial (ClinicalTrials.gov identifier: NCT02383797) of live VZV vaccine on five subjects with
CHH who lacked varicella history, had no clinical symptoms of immunodeficiency, and
were seronegative for VZV; humoral and cellular immunologic responses were assessed
post-immunization.
Results: A large proportion of patients have been immunized with live viral vaccines,
including measles-mumps-rubella (MMR) (n = 40, 38%) and VZV (n = 10, 10%) vaccines,
with no serious adverse events. Of the 50 patients tested for antibodies, previous
immunization has been documented with MMR (n = 22), rubella (n = 2) and measles
(n = 1) vaccines. Patients with CHH demonstrated seropositivity rates of 96%/75%/91%
to measles, mumps and rubella, respectively, measured at a medium of 24 years post-
immunization. Clinical trial participants developed humoral and cellular responses to VZV
vaccine. One trial participant developed post-immunization rash and knee swelling, both
resolved without treatment.
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Conclusion: No serious adverse events have been recorded after immunization with
live viral vaccines in Finnish patients with CHH. Patients generate humoral and cellular
immune response to live viral vaccines. Immunization with live vaccines may be
considered in selected CHH patients with no or clinically mild immunodeficiency.
Keywords: clinical trial, combined immunodeficiency, immunization, MMR, RMRP, vaccination, varicella
zoster virus
INTRODUCTION
Cartilage-hair hypoplasia (CHH, MIM #250250) is a rare
skeletal dysplasia with combined immunodeficiency. CHH
is caused by mutations in the RMRP gene, encoding the
RNA component of the mitochondrial RNA-processing
endoribonuclease RNase MPR (1). Impaired RMRP functioning
results in cell cycle disturbances, altered telomere biology
and changes in gene regulation (2–4). Patients with CHH
demonstrate highly variable degree of immune defect,
ranging from asymptomatic lymphopenia to severe combined
immunodeficiency necessitating hematopoietic stem cell
transplantation (5, 6).
The first report on CHH among the Amish described fatal
outcomes after varicella zoster virus (VZV) primary infection (7).
Since then, several CHH patients with severe varicella, but not
fatalities, have been reported (8–12). In the large Finnish case
series published in 1990s, only two out of 56 patients with a
history of varicella had required hospitalization (13). In a more
recent Amish series of 25 patients, neither antiviral medications
nor hospitalizations were needed for varicella (14).
Patients with CHH can develop fatal complications after
administration of live viral vaccines against smallpox or polio (15,
16). The development of humoral or cellular response after live
vaccine administration has not been previously assessed in CHH.
CD4+ cells producing interferon gamma (IFN-γ) contribute
significantly to the immunity from VZV, and measurement of
IFN-γ response represents a simple method for evaluation of
VZV-specific cellular immunity (17, 18).
Live vaccines are generally contraindicated in patients with
combined immunodeficiency, although they can be tolerated
in milder syndromes (19). Measles-mumps-rubella (MMR) and
VZV vaccines are safe in children with partial DiGeorge
syndrome who have CD4 + T cell counts of ≥500 cells/mm3
(19). In children infected with human immunodeficiency virus,
live vaccines are considered safe if CD4 + T cell count is >200
cells/mm3 or >15% (19).
In order to enable evidence-based decisions on the
immunization of patients with CHH, we collected clinical
data on the course of live-vaccine preventable diseases and
analyzed vaccination and serologic data for the administered
live viral vaccines in a large cohort of Finnish CHH patients,
and then conducted a clinical trial with live VZV vaccine in this
patient population.
Abbreviations: CHH, cartilage-hair hypoplasia; IFN-γ, interferon gamma; MMR,
measles, mumps, rubella; PBMC, peripheral blood mononuclear cells; VZV,
varicella oster virus.
MATERIALS AND METHODS
The study protocol and the clinical trial (ClinicalTrials.gov
identifier: NCT02383797, registered on March 9, 2015) were
approved by the Institutional Ethics Committee at Helsinki
University Hospital and University of Helsinki, Finland.
Additional approval for the clinical trial was obtained from the
Finnish Medicines Agency (FIMEA). The study was conducted
in accordance with the Declaration of Helsinki and national and
institutional standards. All participants and/or caregivers signed
informed consents.
Clinical and Laboratory Data
Clinical data, including data on live-vaccine preventable diseases,
were obtained from the patients directly, as well as retrospectively
from health records, as part of our previous studies exploring
characteristics and natural course of CHH in the Finnish cohort
(5, 13, 20, 21). Only provider-recorded data in the patients’
immunization certificates were considered reliable and were
included in the analysis of immunizations. The researchers had
access to data on all hospitalizations of the study patients,
beginning from 1969, via the Health Registers described in detail
previously (21).
Serum samples were obtained from patients during clinical
visits as part of our previous study (5). All patients who agreed
to blood sampling were included, except those with ongoing
immunoglobulin replacement therapy. The patients were not
selected on the basis of the history of live-vaccine preventable
diseases or immunization with live vaccines. Samples were
analyzed by enzyme immunoassays for the presence of antibodies
to measles, mumps, rubella, and VZVs. Reference values of the
local laboratory (HUSLAB) were applied, and the titers were
considered protective if over 15 EIU for rubella and VZVs, while
for antibodies against measles and mumps viruses, qualitative
assays were used.
Clinical Trial of Live Varicella Vaccine
We conducted an open-label clinical trial on live VZV vaccine
(Figure 1). Of the 120 patients with CHH in the Finnish Skeletal
Dysplasia Register, we recruited five patients. Inclusion criteria
were: (1) genetically confirmed CHH, (2) age >12 months, and
(3) no history of varicella. Exclusion criteria were (1) history
of immunization against VZV, (2) positive serum antibodies for
VZV, (3) low CD4 + T cell counts (<15% or <200 cells/mm3),
(4) clinical signs of severe immunodeficiency, or (5) ongoing
immunoglobulin replacement therapy.
In 2015–2017, all recruited patients were given one or two
doses of Varilrix R©, a live-attenuated VZV Oka strain vaccine,
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FIGURE 1 | Recruitment to the clinical trial of safety and efficacy of live varicella zoster virus vaccine in patients with cartilage-hair hypoplasia.
subcutaneously, by the nurses in the health care facilities. One
dose contained at least 103.3 plaque forming units of VZV.
A second dose was administered if the serologic response after
primary immunization was negative.
Blood samples were drawn pre-immunization and 4-6 weeks
post-immunization for evaluation of humoral and cellular
responses. Humoral responses were assessed by measurement
of serum VZV-specific antibodies by enzyme immunoassay in
HUSLAB. Cellular responses were assessed by elispot using
cryopreserved peripheral blood mononuclear cells (PBMC).
Control PBMC samples were obtained from (1) healthy adult
volunteers with a history of varicella disease, (2) CHH families,
healthy siblings who had been immunized against varicella, and
3) one patient with CHH and a history of varicella.
Peripheral blood mononuclear cells were isolated from
heparinized blood samples by Ficoll centrifugation. The isolated
cells were counted and frozen in RPMI1640 cell culture medium
containing 10% heat-inactivated human male serum (Innovative
Research, Peary Court Novi, MI, United States) and 10%
Dimethyl sulfoxide. Freezing of the isolated PBMCs to −80◦C
was done gradually in a temperature-controlled way in 1.8 ml
cryotubes using isopropanol-filled cryofreezing containers. The
next day the frozen cells were transferred to automated liquid
nitrogen freezer (AGA, Finland) for long term storage at
−180◦C until use.
Peripheral blood mononuclear cells from patients with CHH
and controls were subjected to IFN-γ elispot antigen response
analysis (3420-4HST-2, MabTech, Nacka Strand, Sweden). The
elispot was performed according to manufacturer’s protocol with
24 h stimulation with VZV antigen preparation (PR-BA104, Jena
Bioscience, Löbstedter, Germany). Shortly, thawed PBMC were
cultured on IFN-γ elispot strips in CTL-test medium (CTLT-
010, Cellular Technology Limited, OH, United States) in 5%
CO2 humidified incubator at 37◦C. For antigen response, cells
in triplicate wells were stimulated with 2 ug of VZV antigen
and compared to CTL-test only negative controls. MabTech anti-
CD3 (1:1000) was used as positive control to TCR-stimulant for
T cells. The IFN-γ spots were made visible with streptavidin-
HRP enzymatic assay (3420-4HST-2, MabTech) and the number
of IFN-γ spots were counted with elispot reader system (Elispot
Reader System ELRIFL04, AID, Strassberg, Germany) with
cutoff settings for a size and staining intensity of the positive
spots deriving from the corresponding positive and negative
control spots. The identity of patient and control samples
was blinded during the elispot analysis. The statistical analysis
of the elispot data (Paired-Wilcoxon) was done in RStudio
(1.25) running R (3.6.2) with packages (rstatix, ggpubr, and
tidyverse) available in r-project (cran.r-project.org). If patient
had received two doses of vaccine, the data from the sample
collected after the second dose was used in the analysis. One
sample (vaccinated healthy control) was dropped from the
data due to very low level of reactive T cells in anti-CD3
positive control.
All patients/caregivers were instructed to report any adverse
reactions immediately to the researchers and were additionally
contacted by phone 4–6 weeks post-immunization to record
potential adverse events. In addition, patient records of all clinical
trial participants were assessed at the time of writing (3–5 years
post-immunization) to check for possible long-term adverse
events or breakthrough VZV infection.
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RESULTS
Cohort Description
Of the identified 120 patients with CHH in Finland, informed
consent for the use of clinical and laboratory data was obtained
from 104 patients during our previous studies (Figure 1). All
patients were either homozygous or compound heterozygous for
the g.71A > G RMRP mutation.
The clinical characteristics of this cohort have been reported
in our recent publication (20), According to our clinical
immunodeficiency categorization (21) and based on data on
childhood symptoms available in 103/104 patients, 62 patients
were classified as clinically asymptomatic, another 28 individuals
demonstrated symptoms of humoral immunodeficiency with
recurrent respiratory tract infections and/or sepsis, and the
remaining 13 patients were regarded as having combined
immunodeficiency in childhood, based on the additional features
of autoimmunity or opportunistic infections. During lifetime,
twelve patients had received immunoglobulin replacement
therapy and one patient had undergone a hematopoietic stem
cell transplant. Retrospective laboratory data demonstrated
lymphopenia in 36/83 (43%) patients in childhood and in 37/74
(50%) patients in adulthood.
Live-Vaccine Preventable Diseases in
Patients With CHH
A significant number of patients reported history of measles
(n = 32), mumps (n = 24) and/or rubella (n = 18) (Table 1),
that, in the majority of patients, was also confirmed from the
hospital records. All cases occurred in unvaccinated patients,
prior to the 1980s, and had been diagnosed clinically. No
hospitalizations were linked to measles, mumps, or rubella. Also,
no long-term complications have been documented, including no
cases of measles-associated subacute sclerosing panencephalitis
or rubella-associated granulomatous skin lesions.
A history of varicella was reported in 73 patients with
CHH. In addition, five more patients were seropositive for VZV
despite negative clinical history. Of these 78 patients, seven
were hospitalized for varicella due to severe disease, at least
two of whom had concomitant pneumonia, all seven recovered.
In addition, nine more patients were treated with acyclovir
immediately after the onset of rash, which successfully prevented
the severe course of varicella, and eight more individuals were
administered VZV-specific immunoglobulin after a contact with
varicella and did not develop disease.
Immunization With Live Viral Vaccines in
Patients With CHH
Historically, measles vaccine was used in Finland in 1975–1982,
rubella vaccine in 1975–1988, and MMR vaccine has been used
since 1982. Written evidence of immunization was available in
90/104 patients, and the majority of them (96%, 86/90) have
been vaccinated with one or more live vaccines (Table 1). No
hospitalizations or serious complications were reported after any
live vaccine administration, not even after immunization against
smallpox, polio and yellow fever.
For measles-containing vaccines, one patient received the
first dose in adulthood, otherwise primary immunization was
performed in childhood, at median age of 1.7 years (range 1.1–
12.6 years).
Prior to the initiation of our clinical trial, we were aware of
five patients with CHH successfully immunized with live VZV
vaccine during the second year of life, with no adverse events.
Serology for Measles, Mumps, Rubella,
and Varicella in Patients With CHH
Of the 50 patients tested for antibodies against measles (n = 50),
mumps (n = 48), rubella (n = 48), and varicella (n = 50)
viruses, previous immunization has been documented with MMR
(n = 22), VZV (n = 9), rubella (n = 2) and measles (n = 1) vaccines.
For varicella, all patients with a history of disease or
immunization showed durable humoral response with 100%
(44/44) of seropositivity when tested (Table 2). For measles, 100%
(15/15) of patients with a history of disease had measurable
TABLE 1 | Live vaccine preventable disease history, live vaccine immunization history and serological testing in 104 patients with CHH.








Measles Measles 32 12 0 44/50 (88)
Mumps Mumps 24 NA NA 33/48 (69)
Rubella Rubella 18 8 0 40/48 (83)
MMR NA 40 0 NA
Polio Sabin 0 37 0 n/a
Rota virus Rota virus n/a 2 0 n/a
Smallpox Smallpox 0 22 0 n/a
Tuberculosis BCG 1 78 0 n/a
Varicella VZVb 73 10 1c 49/50 (98)d
Yellow fever Yellow fever 0 1 0 n/a
BCG bacillus Calmette–Guérin vaccine, MMR measles, mumps and rubella combined vaccine, n number of patients, n/a not accessed, NA not applicable, VZV varicella
zoster virus. aPost-vaccination serology results only were reported in those immunized against varicella. bPatients enrolled in the clinical trial were also included.
cComplications are described in detail under the section Clinical trial of live varicella zoster virus vaccine in patients with CHH. dSeronegative patient had no history
of varicella or VZV vaccine administration, but deceased before enrollment into VZV vaccine clinical trial.
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TABLE 2 | Results of antibody measurements for measles, mumps, rubella (MMR)
and varicella zoster viruses from serum samples of patients with cartilage-hair
hypoplasia.
Disease Clinical history Immunized Serology
positive
[n/tested (%)]
Measles Yes: 32 Yes: 4 3/3 (100)
No/no data: 28 12/12 (100)
No/no data: 72 Yes: 39 19/20 (95)
No/no data: 34 10/15 (67)
Mumps Yes: 24 Yes: 2 1/1 (100)
No/no data: 22 11/13 (85)
No/no data: 80 Yes: 37 15/20 (75)
No/no data: 43 6/14 (43)
Rubella Yes: 18 Yes: 4 2/2 (100)
No/no data: 14 11/11 (100)
No/no data: 86 Yes: 43 18/20 (90)
No/no data: 43 9/15 (60)
Varicella Yes: 73 Yes: 0 –
No/no data 73 35/35 (100)
No/no data: 31 Yes: 10 9/9 (100)
No/no data: 21 5/6 (83)
antibodies, as had 96% (22/23) immunized patients (Table 2). For
mumps, seropositivity was observed in 86% (12/14) of patients
with a history of disease and in 75% (15/20) of immunized
patients (Table 2). For rubella, these proportions were 100%
(13/13) and 91% (20/22), respectively (Table 2). In terms
of the clinical staging of immunodeficiency, all seronegative
patients were asymptomatic, except for two patients with
combined immunodeficiency, of whom one did not develop
antibodies against measles and the other against mumps after
MMR vaccination.
Median time between the last dose of measle-containing
vaccines and serum sampling for serology was 24.6 years (range
0.3–36.9 years). This median time interval was similar for
MMR and for rubella-containing vaccines (24.7 and 24.9 years,
respectively). All five patients immunized with live VZV vaccine,
had detectable antibodies against VZV in serum 5–19 years
(median 17 years) post-immunization.
Clinical Trial of Live Varicella Zoster Virus
Vaccine in Patients With CHH
Table 3 summarizes the results of the clinical trial on live VZV
vaccine in five patients with CHH. We immunized four children
and one adult, all with clinically silent immunodeficiency.
Three patients were lymphopenic, with various abnormalities
in lymphocyte subpopulations. Lymphocyte responses to
stimulation with mitogens were normal in all patients. All five
patients had normal levels of immunoglobulin G.
None of the four immunized children developed adverse
events. All five patients are well 2.8–4.5 years post-immunization,
and no breakthrough varicella has been reported. Patient 5
reported a self-limited upper respiratory tract infection two
weeks post-immunization. He then developed a rash during the
third week post-immunization when few painless yellow-reddish
round papules and ulcers (but not vesicles) 0.5 cm in size
appeared on his abdomen, neck, and head within several
days. The rash persisted unchanged for a week and then
gradually disappeared. In addition, the patient developed
swelling and morning stiffness in his right knee three weeks post-
immunization, which did not disturb his walking and cycling.
The patient declined antiviral and anti-inflammatory therapy
TABLE 3 | Summary of the clinical trial of live varicella zoster virus vaccine in patients with cartilage-hair hypoplasia.
Patient 1 2 3 4 5
Age at primary immunization, years 1·5 2·7 6 16 45
Symptoms of combined immunodeficiency prior to immunizationa None None None None None
Laboratory parameters prior to immunization
Total lymphocyte count, cells/mm3 2112 3020 960 1210 1590
CD3 + T cell count, cells/mm3 1150 2240 580 810 1200
CD4 + T cell count, cells/mm3 827 1482 294 543 625
CD8 + T cell count, cells/mm3 140 530 110 140 590
CD19 + B cell count, cells/mm3 290 580 120 130 160
CD16/56 + NK cell count, cells/mm3 310 110 170 90 160
Lymphocyte response to stimulation with PHA Normal Normal Normal Normal Normal
Number of vaccine doses 2 2 1 2 1
Time interval between vaccine doses, months 6 6 n/a 4.5 n/a
VZV-specific immunoglobulin G after the first dose neg neg pos neg pos
VZV-specific immunoglobulin G after the second dose pos pos NA pos NA
Cellular response by elispot after the first dose neg pos pos pos pos
Cellular response by elispot after the second dose pos n/a NA pos NA
Vaccine adverse events None None None None Yesb
Numbers in bold represent cell counts below the normal range for age. n/a not available, NA – not applicable, neg – negative, PHA – phytohemagglutinin, pos – positive,
VZV – varicella zoster virus. a Including severe or opportunistic infections, autoimmunity, or malignancy. bPost-immunization adverse events (rash and knee swelling) are
described in detail in text.
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FIGURE 2 | Varicella zoster virus antigen response in CHH patient samples.
Peripheral blood mononuclear cells of naïve and post-vaccine paired patient
samples showed statistically significant induction of cellular immunity in
interferon-γ elispot antigen assay. The level of induction (mean, black lines)
was similar to a single healthy control.
and reported no complaints on the follow-up seven weeks
post-immunization. There was no viremia at the time of rash,
confirmed by negative blood VZV nucleic acid testing.
Three patients who did not develop measurable humoral
response after the first vaccine dose demonstrated seroconversion
after the second immunization. All patients also demonstrated
the development of cellular response post-immunization when
measured by elispot, 4/5 after the first vaccine dose (Figure 2).
DISCUSSION
This is the first study describing the administration of live viral
vaccines in a large cohort of patients with CHH. We demonstrate
the safety and efficacy of MMR and VZV vaccines in this
patient population, based on the retrospective data on provider-
recorded immunizations, absence of breakthrough infections or
hospitalizations linked to immunizations, as well as the durable
serologic response. We also present the results of a clinical trial
of live VZV vaccine in patients with CHH, which showed the
generation of both humoral and cellular immune responses.
Among the participants of our clinical trial, the incidence of
varicella-like post-vaccination rash was 20% (1/5), compared
with the reported rates of 0–7% in healthy individuals (22).
Prior to the 1980s, when MMR immunization was introduced
in Finland, many patients with CHH had contracted MMR-
diseases with uneventful course. This is in line with the generally
milder immunodeficiency phenotype in Finnish individuals with
CHH who rarely develop severe opportunistic infections (21).
However, varicella clearly is an exception, as many patients
with CHH suffer from prolonged rash and fever and some
develop pneumonia and require hospitalization (13). Many
patients with CHH are pre-emptively treated with acyclovir and
given VZV immunoglobulin for the post-exposure prophylaxis.
Immunization against VZV may obviate the need for prophylaxis,
antiviral treatment and hospitalizations. The same considerations
can be applied to the MMR vaccine.
Patients with CHH mount robust humoral immune
response to measles and varicella (both natural infection
and immunization), which remains measurable for decades.
Antibodies to mumps either do not develop or wane over time
in a significant proportion (14–25%) of patients with CHH,
raising the concern about insufficient immunity against mumps.
Also, rarely, patients with CHH may not develop seropositivity
for rubella after MMR administration. Therefore, antibody
measurement should be routinely used to assess vaccination
responses in patients with CHH and booster doses should be
given in case of insufficient immunity.
The pattern of seropositivity to MMR and VZV in patients
with CHH are similar to those in healthy individuals, with good
responses to measles, varicella and rubella, but lower rates of
seropositivity to mumps (23, 24). However, in our clinical trial
of VZV vaccine, 60% (3/5) of participants failed to develop
antibodies against VZV after the single vaccine dose, while in
healthy children this proportion is 24% (25).
This is the first study describing the production of IFN-γ
in stimulated PBMC from patients with CHH. Our assessment
of cellular response to VZV vaccine demonstrate that patients
with CHH develop cellular immunity probably comparable to
healthy immunized controls. The comparison was problematic
due to the small number of healthy immunized controls.
Antibodies are essential to neutralize pathogens in extracellular
space. However, cellular immunity is critical for controlling
and containing intracellular pathogens, especially viruses with
the ability to form latency, such as VZV. Thus, the protection
against VZV is provided by multitude of simultaneously acting
immunological mechanisms (26). Here, we observed clear
cellular responses in two CHH patients after the first vaccine
dose despite no development of antibodies to VZV. This may
be explained by delayed antibody production consistent with
combined immunodeficiency in CHH. The activation of cellular
response against VZV in CHH patients suggests that these
individuals may have sufficient immune protection against VZV
despite the decreased humoral response. Our data support the
recommendation of two doses of VZV vaccine, not single dose, to
ensure optimal immune response of both, humoral and cellular,
arms of the immune system.
Although there were no reported long-term consequences
of live vaccines in our cohort, clinicians and patients should
be aware of the risk of delayed development of vaccine-strain
rubella virus-associated skin granulomas in patients with CHH
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(27). In addition, there were no reactivation of vaccine-strain
VZV in our patients, possibly reflecting the effective cellular
immunity against VZV. However, such a reactivation, occurring
even years after primary immunization, and accompanied by
central nervous system infection, has been described, both in
immunocompetent and immunocompromised adolescents (28).
Laboratory parameters do not correlate with clinical
severity or prognosis in CHH (21), and our study reports
successful immunization of lymphopenic patients, therefore mild
lymphopenia itself should not be an absolute contraindication
for live vaccine administration in CHH. Clinicians can utilize
laboratory criteria used in the management of patients with
human immunodeficiency virus infection or patients with partial
DiGeorge syndrome to make decisions on immunization in
patients with CHH. Importantly, all vaccinated patients in our
clinical trial demonstrated normal lymphocyte proliferation
responses to mitogens prior to immunization. Immunization
may be considered in clinically asymptomatic patients
with CHH or those with mild recurrent respiratory tract
infections and no other clinical features of immunodeficiency.
However, individuals considered for the immunization should
be selected cautiously and the qualitative assessment of
lymphocyte subsets and function should be performed prior to
immunization. Even though several patients with clinical features
of combined immunodeficiency have been immunized with
MMR successfully, we advise against live vaccine administration
to these patients.
The strengths of our study are (1) the large number of
patients for whom clinical and laboratory data were available,
(2) written evidence of immunization in the majority of the
study participants, (3) long-term follow-up data and assessment
of serologic response to immunization in the long-term, as well as
(4) assessment of both, humoral and cellular immune responses
in a clinical trial. The drawbacks of our clinical trial include
small sample size and relatively short follow-up time, calling for
further studies with longer follow-up to evaluate the efficacy and
long-term safety of VZV vaccine.
In conclusion, we provide retrospective and prospective
data on the safety and efficacy of live viral vaccines in
Finnish patients with CHH. Immunization with live vaccines
should be considered in selected CHH patients with clinically
mild immunodeficiency.
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